Cytorex Biosciences Inc. (Cytorex), a South Florida biotechnology company with research and development facilities in Texas, announced today the publication of the results of a study that determined the effect of Cytoreg® ionic therapy on acid-base balance and its biochemical and physiological effects in a Wistar rat model as determined by arterial blood gas analysis.
The acidic nature of Cytoreg® ionic therapy could potentially alter the pH and levels of ions and dissolved gases in the blood. The results demonstrate that Cytoreg® does not alter normal blood pH, ion levels or carbon dioxide content, but increases oxygen levels in rats. These data are consistent with the excellent tolerability of intravenous Cytoreg observed in In Vivo Models using rabbits and dogs.
"The results of this study demonstrate that the partial pressures of CO2 (pCO2), the main gas that provides information on ventilation, oxygenation and acid-base balance levels, remain constant. This behavior of pCO2 levels shows that Cytoreg® ionic therapy, does not alter respiratory stability or alveolar ventilation, so that adequate CO2 elimination is performed in adequate time and without difficulty; ionic does not compromise the physiological integrity of the organs (lung and kidney) responsible for maintaining acid-base balance; it maintained hydration and electrolyte balance in the In Vivo model used; that pO2 increases after Cytoreg® administration. This could result in a better oxygen uptake by the tissues and have a beneficial therapeutic effect in diseases characterized by hypoxia", summarizes Katiuska Villasana, from the Department of Biology of the Faculty of Sciences, Universidad de los Andes - ULA-, Merida, Venezuela and leader of the research project.
"For Cytorex it is very pleasing to announce results of the advances in the fulfillment of our Research and Development Plan for our ionic therapeutic technology. These results in particular offer a range of therapeutic targets that we can reach with the ionic transport complex that Cytoreg® therapy conjugates. The mere increase in pO2, after administration, is therapeutically very decisive as it will not only improve oxygen uptake in tissues to aid healing and skin toning, but also impacts other therapeutic benefits, such as in pathologies characterized by hypoxia or poor oxygen environment", stated William Jimenez, Chairman of the Board of Directors of the company.
About Cytorex Biosciences, Inc.
Cytorex Biosciences, Inc. is a small innovative biotechnology company based in South Florida with a research and development coordination center in Kingwood, Texas focused on the development and research of ionic therapeutic agents, based on Cytoreg® ionic therapeutic technology, for the development of targeted therapeutic agents for the treatment of pathologies such as cancer, autoimmune diseases, neurodegenerative diseases, kidney stones, bacterial-derived pathologies, viruses such as Ebola and SARS-CoV-2 among other pathologies. Cytorex has worldwide intellectual property rights on its technologies, with other new patents pending and others in development. Cytorex Biosciences Inc. is currently in the final stage of the preclinical phase for PRE-IND review by USFDA of its ionic therapeutic agent designed for the treatment of Glioblastoma Multiforme brain tumors.